Co-administration of Dual-Targeting Nanoparticles with Penetration Enhancement Peptide for Antiglioblastoma Therapy
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Chemotherapy is an indispensable auxiliary treatment for glioma but highly limited by the existence of both blood-brain barrier (BBB) and blood-brain tumor barrier (BBTB). The dysfunctional brain tumor blood vessels and high interstitial pressure in glioma also greatly hindered the accumulation and deep penetration of chemotherapeutics into the glioma. Lactoferrin (Lf), with its receptor overexpressed on both the brain endothelial cells and glioma cells, was here functionalized to the surface of poly(ethylene glycol)-poly(lactic acid) nanoparticles to mediate BBB/BBTB and glioma cell dual targeting. tLyP-1, a tumor-homing peptide, which contains a C-end Rule sequence that can mediate tissue penetration through the neuropilin-1-dependent internalization pathway, was coadministrated with Lf-functionalized nanoparticles (Lf-NP) to enhance its accumulation and deep penetration into the glioma parenchyma. Enhanced cellular association in both BCEC and C6 cells, increased cytotoxicity of the loaded paclitaxel, and deep penetration in the 3D glioma spheroids was achieved by Lf-NP. Following coadministration with tLyP-1, the functionalized nanoparticles obtained improved tumor targeting, glioma vascular extravasation, and antiglioma efficacy. The findings here suggested that the strategy by coadministrating BBB/BBTB and glioma cells dual-targeting nanocarriers with a tumor penetration enhancement peptide represent a promising platform for antiglioma drug delivery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.063 · Cited by 1,324
C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration
Teesalu, T., Sugahara, K. N., Kotamraju, V. R., & Ruoslahti, E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908201106 · Cited by 812
Demeule, M., Currie, J., Bertrand, Y., Ché, C., Nguyen, T., Régina, A., Gabathuler, R., Castaigne, J., & Béliveau, R. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05492.x · Cited by 557
Cited by
Tumor penetrating peptides for improved drug delivery
Ruoslahti, E. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.03.008 · Cited by 459
Engineered nanomedicines with enhanced tumor penetration
Ding, J., Chen, J., Gao, L., Jiang, Z., Zhang, Y., Li, M., Xiao, Q., Lee, S. S., & Chen, X. (2019) · Nano Today · doi:10.1016/j.nantod.2019.100800 · Cited by 420
Self-citationBarriers to drug delivery in solid tumors
Sriraman, S. K., Aryasomayajula, B., & Torchilin, V. P. (2014) · Tissue Barriers · doi:10.4161/tisb.29528 · Cited by 338
Strategies to improve the EPR effect: A mechanistic perspective and clinical translation
Ikeda-Imafuku, M., Wang, L. L.-W., Rodrigues, D., Shaha, S., Zhao, Z., & Mitragotri, S. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.043 · Cited by 330
Tumor target amplification: Implications for nano drug delivery systems
Seidi, K., Neubauer, H. A., Moriggl, R., Jahanban-Esfahlan, R., & Javaheri, T. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.02.020 · Cited by 145
Ferraris, C., Cavalli, R., Panciani, P. P., & Battaglia, L. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s231479 · Cited by 131
Metadata
- Authors
- Miao, D., Jiang, M., Liu, Z., Gu, G., Hu, Q., Kang, T., Song, Q., Yao, L., Li, W., Gao, X., Sun, M., & Chen, J.
- Venue
- Molecular Pharmaceutics
- Publisher
- American Chemical Society (ACS)
- Published
- 2013-12-02
- Volume
- 11
- Issue
- 1
- Pages
- 90-101
- ISSN
- 1543-8384 (ISSN-L)
- 1543-8392
- OpenAlex
- W2333918108
- Cited by
- 84
- References
- 4
- FWCI
- 2.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.